Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults

A journal article on highly active antiretroviral therapy (HAART)

From:
Department for International Development
Published
1 September 2014
Document Type:
Journal Article
Theme:
Health
Authors:
Gbabe, O.F, Okwundu, C.I., Dedicoat, M, Freeman, E.E.

Abstract

Kaposi’s sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence. However, Kaposi’s sarcoma continues to be diagnosed in HIV-infected patients.

The objectives of this paper:

To assess the added advantage of chemotherapy plus HAART compared to HAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi’s sarcoma.

This research is supported by the Department for International Development’s Evidence Building and Synthesis Research Programme which is led by the Liverpool School of Tropical Medicine

Citation

Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE : Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. The Cochrane database of systematic reviews DOI: 10.1002/14651858.CD003256.pub2

Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults

Updates to this page

Published 1 September 2014
Contents